Medtronic's tremor control therapy cleared by FDA:
This article was originally published in Clinica
Medtronic has received clearance from the FDA to market its Activa implantable device for treating tremor in the US. The system is intended for control of unilateral essential tremor and tremor associated with Parkinson's disease. Medtronic, based in Minneapolis, Indiana, estimates that at least one million people in the US each year suffer from essential tremor and a further 500,000 people are affected by Parkinson's disease-related tremor.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.